Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience.

Baltruškevičienė E, Mickys U, Žvirblis T, Stulpinas R, Pipirienė Želvienė T, Aleknavičius E.

Acta Med Litu. 2016;23(1):24-34. doi: 10.6001/actamedica.v23i1.3267.

2.

Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer: a consensus of Lithuanian medical oncologists, radiation oncologists, endocrinologists, and family medicine physicians.

Juozaitytė E, Aleknavičius E, Jančiauskienė R, Cesas A, Pipirienė-Želvienė T, Liutkauskienė S, Krasauskienė A, Vencevičienė L.

Medicina (Kaunas). 2014;50(4):197-203. doi: 10.1016/j.medici.2014.09.004. Epub 2014 Oct 1.

3.

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, González-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI; ATHENA Study Group.

Ann Oncol. 2011 Mar;22(3):595-602. doi: 10.1093/annonc/mdq430. Epub 2010 Sep 5.

4.

The value of clinical prognostic factors for survival in patients with invasive urinary bladder cancer.

Asadauskiene J, Aleknavicius E, Pipiriene-Zelviene T, Jankevicius F.

Medicina (Kaunas). 2010;46(5):305-14.

Supplemental Content

Loading ...
Support Center